Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study.

ABSTRACT:

Study question

How safe is live attenuated influenza vaccine (LAIV), which contains egg protein, in young people with egg allergy?

Methods

In this open label, phase IV intervention study, 779 young people (2-18 years) with egg allergy were recruited from 30 UK allergy centres and immunised with LAIV. The cohort included 270 (34.7%) young people with previous anaphylaxis to egg, of whom 157 (20.1%) had experienced respiratory and/or cardiovascular symptoms. 445 (57.1%) had doctor diagnosed asthma or recurrent wheeze. Participants were observed for at least 30 minutes after vaccination and followed-up by telephone 72 hours later. Participants with a history of recurrent wheeze or asthma underwent further follow-up four weeks later. The main outcome measure was incidence of an

SUBMITTER: Turner PJ 

PROVIDER: S-EPMC4673102 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature